Tag: TherapeuticsMD Inc.

  • Multiple SEC Filings: TherapeuticsMD Inc. (TXMD) stock Falls After Hours

    Multiple SEC Filings: TherapeuticsMD Inc. (TXMD) stock Falls After Hours

    On March 23, TherapeuticsMD Inc. (TXMD) submitted multiple filings with the U.S. Securities Exchange Commission. Consequently, the stock suffered a downfall in the after-hours session.

    During the regular session, the stock went up by 8.87% at its closing price of $0.4356. The volume of shares traded during the session was just above the average at 8.06 million against 7.76 million. In the following after-hours session, TXMD saw a reversal with a loss of 12.76%. Hence, the stock was trading at a price of $0.3800 per share in the after-hours while the volume of shares exchanged was 782.16K.

    The pharmaceutical company, TherapeuticsMD Inc. develops products for women. Currently, the company has a market capitalization of $170.01 million with its 424.93 million shares outstanding.

    TXMD’s SEC Filings

    On Wednesday, the company submitted three SEC filings: i) 10-K: Annual report for the year ending December 31, 2021; ii) POSASR: Post-effective Amendment to an automatic shelf registration statement; and iii) SC 13D/A: General statement of acquisition of beneficial ownership – amendment.

    Source: Uni of Utah

    Previously, on March 18, the company had filed a current report on Form 8-K regarding Nasdaq’s notification and certain changes in the company’s leadership. As per the filing, having failed to regain compliance with Nasdaq’s minimum bid requirement in the given period, TXMD has requested a hearing before Nasdaq’s hearing panel. Moreover, the company’s CFO and Principal Financial Officer James C. D’Arrecca will be resigning on April 1, 2022. Thus, VP-Finance & Chief Accounting Officer Michael C. Donegan will succeed Mr. D’Arrecca on an interim basis.

    Q4 2021 Financial Results

    On March 10, the company declared its financial results for the fourth quarter of 2021.

    In Q4 2021, TXMD generated net product revenue of $7.8 million for ANNOVERA, $6.7 million for IMVEXXY®, and $2.7 million for BIJUVA®.

    Furthermore, the company incurred a net loss of $43.0 million in Q4 2021, against $42.1 million in Q4 2020. Resultantly, the net loss per share was $0.10 and $0.15 in Q4 of 2021 and 2020 respectively.

    Additionally, the cost of goods was $4.7 million while the product gross margin was 75% in the quarter.

    The company ended the quarter with $65.1 million in cash on hand on December 31, 2021.

    TXMD’s Divestiture of vitaCare

    On March 7, TXMD announced its definitive agreement for divesting its vitaCare Prescriptions Services to GoodRx for $150 million in cash. The agreement also includes additional consideration of $7 million based upon vitaCare’s performance through 2023. The transaction is expected to close in Q2 2022.

  • 15 Top Performing Stocks In Healthcare Industry

    15 Top Performing Stocks In Healthcare Industry

    The health care industry is considered to be the opportunity-rich industry. The demand in this industry is continuously increasing. Emerging technologies also play a very important role in the health care industry. Complex health and technology ecosystems and increasing consumer expectations are the major challenges which the health care industry is facing. Customers’ main priority is affordable and efficient drugs.

    If we look at the Drug manufacturers and specialty generic industry, this industry has seen a huge transformation over the last two decades. This industry is always striving to change fast enough to keep up with regulatory and patients needs. Currently, the healthcare industry has faced the major challenge of the COVID-19 pandemic. It is important to focus on what is happening in the market to increase industry growth.

    Here are the 15 leading companies in the Drug Manufacturers and specialty and generic industry:

    Zomedica Pharmaceuticals Corp. (AMEX: ZOM)

    Zomedica Pharmaceuticals Corp. (AMEX: ZOM) shares were trading up 42.86% at $0.10 at the time of writing on Monday. Zomedica Pharmaceuticals Corp. (AMEX: ZOM) share price went from a low point around $0.07 to briefly over $0.50 in past 52 weeks, though shares have since pulled back to $0.10. ZOM market cap has remained high, hitting $79.71M at the time of writing.

    Zomedica Pharmaceuticals Corp. has earlier revealed its proxy solicitor, Alliance Advisors, mailed the letter to selected shareholders in advance of its Annual and Special Virtual-Only Meeting of Shareholders. The virtual meeting is scheduled to hold on September 25, 2020.

    AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX)

    AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) last closed at $1.81, in a 52-week range of $0.70 to $2.68. AcelRx Pharmaceuticals Inc. (ACRX) announced today that the U.S. Army has granted AcelRx with an initial contract of up to approximately $3.6 million for the purchase of DSUVIA to support a study to aid the development of clinical practice guidelines. This company’s market capitalization has remained high, hitting $142.61 million at the time of writing.

    PPD Inc. (NASDAQ: PPD)

    PPD Inc. (NASDAQ: PPD) stock soar by 0.92% to $34.16. The most recent rating by KeyBanc Capital Markets, on June 04, 2020, is at an Overweight. PPD Inc. (PPD) has earlier revealed that it has received the honor of employer of choice around the world. PPD was recognized as a top 50 desirable employer in Bulgaria, according to the second annual Employer of Choice Survey organized by the employer brand and business consulting agency To The Top. This company market capitalization has remained high, hitting $11.61 billion at the time of writing.

    Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)

    Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) last closed at $0.80, in a 52-week range of $0.27 to $1.51. Analysts have a consensus price target of $1.25. Adamis Pharmaceuticals Corporation (ADMP) has earlier revealed the pricing of its previously announced underwritten public offering of 16,129,032 shares of its common stock at a public offering price of $0.62 per share, resulting in gross proceeds of approximately $10,000,000.

    Rockwell Medical Inc. (NASDAQ: RMTI)

    Rockwell Medical Inc. (NASDAQ: RMTI) last closed at $1.76, in a 52-week range of $1.10 to $3.85. Rockwell Medical Inc. (RMTI) has earlier named Russell L. Skibsted, M.B.A., as Executive Vice President, Chief Financial Officer  and Chief Business Officer (CBO), effective from September 15, 2020. This company market capitalization has remained high, hitting $96.44 million at the time of writing.

    TherapeuticsMD Inc. (NASDAQ: TXMD)

    TherapeuticsMD Inc. (NASDAQ: TXMD) stock soars 2.75% to $1.44. The most recent rating by Jefferies, on August 07, 2020, is at an Underperform. TherapeuticsMD Inc. (TXMD) Knight Therapeutics Inc. and TherapeuticsMD, Inc. revealed that they received the approval of BIJUVA® (estradiol and progesterone) capsules by Health Canada. This company has a market capitalization of $368.06 million at the time of writing.

    Zoetis Inc. (NYSE: ZTS)

    Zoetis Inc. (NYSE: ZTS) rose 0.06% after gaining more than $0.01 on Tuesday. Zoetis Inc. (ZTS) has been recognized by Working Mother magazine for its career advancement opportunities, female representation and work-life programs. in the past 52-weeks of trading, Zoetis stock has fluctuated between the low of $90.14 and a high of $165.82. ZTS has moved up 78.59% from its 52-weeks low and moved down -2.92% from its 52-weeks high.  ZTS market cap has remained high, hitting $76.29 billion at the time of writing.

    DURECT Corporation (NASDAQ: DRRX)

    DURECT Corporation (NASDAQ: DRRX) stock drop by -5.41% to $1.75. The most recent rating by Oppenheimer, on July 31, 2020, is at an Outperform. DURECT Corporation (DRRX) has revealed the study design for the Phase 2b AHFIRM clinical trial of DUR-928 in severe alcoholic hepatitis (AH) patients. DURECT Corporation market cap has remained high, hitting $333.92 million at the time of writing.

    Elanco Animal Health Incorporated (NYSE: ELAN)

    Elanco Animal Health Incorporated (NYSE: ELAN) shares headed rising, higher as much as 0.56%. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Overweight. In the past 52-weeks of trading, this company stock has fluctuated between the low of $15.17 and a high of 32.66. Elanco Animal Health Incorporated (ELAN) has moved up 76.01% from its 52-weeks low and moved down -18.25% from its 52-weeks high.

    Guardion Health Sciences Inc. (NASDAQ: GHSI)

    Guardion Health Sciences Inc. (NASDAQ: GHSI) rose 1.22% on Monday. Guardion Health Sciences Inc. (GHSI) share price went from a low point around $0.17 to briefly over $0.95 in the past 52 weeks, though shares have since pulled back to $0.25. Guardion Health Sciences Inc.’s market cap has remained high, hitting $22.26 million at the time of writing.

    Agile Therapeutics Inc. (NASDAQ: AGRX)

    Agile Therapeutics Inc. (NASDAQ: AGRX) shares headed falling, lower as much as -6.89%. The most recent rating by Janney, on April 12, 2019, is at a Buy. In the past 52-weeks of trading, Agile Therapeutics Inc. stock has fluctuated between the low of $0.35 and a high of $4.77. Agile Therapeutics Inc. has moved up 807.14% from its 52-weeks low and moved down -33.37% from its 52-weeks high.

    Momenta Pharmaceuticals Inc. (NASDAQ: MNTA)

    Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) stock drops 0.02% after losing -0.01 on Tuesday. Momenta Pharmaceuticals Inc. (MNTA) share price went from a low point around $12.21 to briefly over $52.45 in the past 52 weeks, though shares have since pulled back to $52.36. Momenta Pharmaceuticals Inc.’s market cap has remained high, hitting $6.24 billion at the time of writing.

    Catalent Inc. (NYSE: CTLT)

    Catalent Inc. (NYSE: CTLT) stock drop 0.86% to $84.81. The most recent rating by Argus, on June 25, 2020, is at a Buy. In the past 52-weeks of trading, Catalent Inc. (CTLT) stock has fluctuated between the low of $31.04 and a high of $95.70. Catalent Inc. has moved up 173.23% from its 52-weeks low and moved down -11.38% from its 52-weeks high.  Catalent Inc. market cap has remained high, hitting $13.94 billion at the time of writing.

    Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD)

    Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) shares headed falling, lower as much as 2.22%. The most recent rating by Northland Capital, on June 17, 2020, is at an Outperform. Ironwood Pharmaceuticals Inc. (IRWD) share price went from a low point around $7.91 to briefly over $14.10 in the past 52 weeks, though shares have since pulled back to $9.48. Ironwood Pharmaceuticals Inc.’s market cap has remained high, hitting $1.54 billion at the time of writing.

    Athenex Inc. (NASDAQ: ATNX)

    Athenex Inc. (NASDAQ: ATNX) last closed at $12.80, in a 52-week range of $5.63 to $18.35. Athenex Inc. (ATNX) has moved up 127.35% from its 52-weeks low and moved down -30.25% from its 52-weeks high.  Athenex Inc. market cap has remained high, hitting $1.14 billion at the time of writing.